Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lipitor Holds Up In Merger Dispute; Warner-Lambert, Pfizer Beat Expectations

Executive Summary

Warner-Lambert's Lipitor is showing no signs of a negative impact from the distractions caused by the hostile takeover bid launched by Warner's marketing partner Pfizer.
Advertisement

Related Content

Aiming For Non-Statin Cholesterol Drug Market, Esperion Takes $33M
Lucentis Fits Genentech’s Small Market/High Need Business Model
Lucentis Fits Genentech’s Small Market/High Need Business Model
Pfizer Sees Neurontin Exclusivity Through 2002, Pregabalin Filing By Year-End
Pfizer Sees Neurontin Exclusivity Through 2002, Pregabalin Filing By Year-End
Forest Celexa
Procter & Gamble Recants: Size Does Matter In Rx Industry
Procter & Gamble Recants: Size Does Matter In Rx Industry
Forest Reclaiming Celexa Ahead Of Warner-Lambert Merger
Warner-Lambert And AHP Plan Protonix Copromotion Agreement
Advertisement
UsernamePublicRestriction

Register

PS035485

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel